Invitation to a Company Update on the COVID-19 Response

LUND (Sweden) - Immunovia invites you to a teleconference (in English) for all stakeholders and media on Wednesday, April 1, 2020 at 16:30 CET.

Mats Grahn, CEO will present an update on the company’s COVID-19 response as well as an update on the activities in preparation for the Q3 2020 launch of IMMray™ PanCan-d and the prospective studies followed by a Q&A session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:

Conference Numbers:

Sweden: +46 (0) 8 50 520 424

Austria: +43 (0) 12530807

Germany: +49 (0) 30 3001 90612

Denmark: +45 3271 4573

Switzerland: +41 (0) 22 592 7103

Spain: +34 91 787 0777

Netherlands: +31 (0) 20 794 8426

United States: +1 212 999 6659

Norway: +47 2156 3318

France: +33 (0) 1 7037 7166

United Kingdom (standard international access): +44 (0) 20 3003 2666

Conference Code: (to provide to the operator) Immunovia

Immunovia Webcast: https://channel.royalcast.com/webcast/immunovia/20200401_1/

For more information, please contact:

Julie Silber, Director of Investor Relations,

Immunovia Email: julie.silber@immunovia.com

Tel: +46 7 93 486 277

There will be an MP3-file available at Immunovia’s webpage under Investors/Audio-Gallery (https://immunovia.com/investors/audio-gallery/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

 

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###

Subscribe

Documents & Links